ArticleCureus2026
Pembrolizumab-Induced Eruptive Keratoacanthomas Managed With Intralesional Corticosteroids: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, is approved for multiple malignancies, including renal cell carcinoma in combination with axitinib. While highly effective, PD-1 blockade can provoke immune-mediated cutaneous adverse events, including eruptive squamous cell carcinomas and keratoacanthomas. These squamoproliferative lesions may reflect a reactive epidermal proliferation triggered by immune activation, potentially through unmasking of subclinical epidermal dysplasia. Histologically, keratoacanthomas and well-differentiated squamous cell carcinomas can be difficult to distinguish, and clinicopathologic correlation is essential for guiding management. We present a case of a patient receiving pembrolizumab and axitinib for renal cell carcinoma who developed a high burden of eruptive squamoproliferative lesions across multiple anatomic sites. Biopsies were interpreted as either well-differentiated squamous cell carcinoma or keratoacanthoma-type squamous proliferations, underscoring the diagnostic ambiguity inherent to these lesions. Most lesions were successfully managed with intralesional triamcinolone, allowing continuation of immunotherapy without interruption. Two subsequent lesions required surgical excision due to clinical concern for invasive behavior, although no aggressive histologic features were identified. This case adds to the growing literature supporting conservative dermatologic management of pembrolizumab-associated squamoproliferative lesions. Unlike previous reports describing only a small number of lesions, this case involved a high lesion burden treated with intralesional corticosteroids across multiple sites, with clearly documented technique and follow-up. The case reinforces the clinical importance of correlating histopathologic findings with therapeutic response and demonstrates that, with appropriate monitoring, immunotherapy can often be continued safely while managing cutaneous findings locally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.